MEN2B
MCID: MLT025
MIFTS: 56

Multiple Endocrine Neoplasia Iib (MEN2B) malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Multiple Endocrine Neoplasia Iib

Aliases & Descriptions for Multiple Endocrine Neoplasia Iib:

Name: Multiple Endocrine Neoplasia Iib 54 13
Multiple Endocrine Neoplasia Type 2b 12 50 24 56 29 42 14 69
Men2b 12 24 56 66
Wagenmann-Froboese Syndrome 12 50 56
Mucosal Neuroma Syndrome 12 50 24
Men 2b 50 24
Multiple Endocrine Neoplasia, Type Iib 54
Multiple Endocrine Neoplasia, Type 3 12
Multiple Endocrine Neoplasia Type 3 56
Multiple Neoplasia 2b 66
Men Type Iib 12

Characteristics:

Orphanet epidemiological data:

56
multiple endocrine neoplasia type 2b
Inheritance: Autosomal dominant; Age of onset: Childhood;

HPO:

32
multiple endocrine neoplasia iib:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 54 162300
Disease Ontology 12 DOID:10016
ICD10 33 E31.23
ICD9CM 35 258.03
MeSH 42 D018814
NCIt 47 C3227
SNOMED-CT 64 61530001
Orphanet 56 ORPHA247709
MESH via Orphanet 43 D018814
ICD10 via Orphanet 34 D44.8
UMLS via Orphanet 70 C0025269
MedGen 40 C0025269
UMLS 69 C0025269

Summaries for Multiple Endocrine Neoplasia Iib

OMIM : 54 Multiple endocrine neoplasia type IIB (MEN2B) is an autosomal dominant hamartoneoplastic syndrome characterized by... (162300) more...

MalaCards based summary : Multiple Endocrine Neoplasia Iib, also known as multiple endocrine neoplasia type 2b, is related to pheochromocytoma and medullary thyroid carcinoma, familial, and has symptoms including constipation, diarrhea and joint laxity. An important gene associated with Multiple Endocrine Neoplasia Iib is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Axon guidance. The drugs Bevacizumab and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, skin and colon, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 An autosomal dominant disease characterized by medullary thyroid carcinoma, pheochromocytoma, multiple mucosal neuromas and intestinal ganglioneuromas, and often a marfanoid habitus and other skeletal abnormalities.

UniProtKB/Swiss-Prot : 66 Multiple neoplasia 2B: Uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.

Related Diseases for Multiple Endocrine Neoplasia Iib

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia Iia Multiple Endocrine Neoplasia Iib
Multiple Endocrine Neoplasia 1 Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia Iib via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 29.8 CALCA GDNF MEN1 RET
2 medullary thyroid carcinoma, familial 10.8
3 multiple endocrine neoplasia iia 10.8
4 multiple endocrine neoplasia 1 10.8
5 gastrinoma 10.3 CALCA RET
6 meigel disease 10.2 GDNF RET
7 pemphigus foliaceus 10.2 CALCA MEN1
8 waardenburg syndrome, type 4a 10.2 EDNRB RET
9 paranasal sinus cancer, adult 10.2 CALCA MEN1
10 hyperparathyroidism, familial primary 10.2 MEN1 RET
11 adult ependymoblastoma 10.2 CALCA MEN1
12 early-onset parkinson disease 10.2 MEN1 RET
13 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.2 GDNF RET
14 ceroid lipofuscinosis, neuronal, 5 10.2 EDNRB RET
15 immunodeficiency by defective expression of hla class 1 10.2 CALCA EDNRB
16 gemistocytic astrocytoma 10.2 CALCA MEN1
17 multiple endocrine neoplasia 10.2
18 hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome 10.2 OSMR RET
19 acute cor pulmonale 10.2 CALCA EDNRB
20 cardioauditory syndrome of sanchez cascos 10.2 CALCA MEN1
21 apocrine adenoma 10.2 EDNRB RET
22 keloids 10.2 CALCA MEN1
23 epidermolysis bullosa, junctional, herlitz type 10.2 CALCA MEN1
24 hemopericardium 10.2 CALCA EDNRB
25 nodular prostate 10.2 CALCA RET
26 infertility 10.2 PTCH1 RET
27 cowden syndrome 3 10.2 CALCA MEN1 RET
28 opioid abuse 10.2 CALCA MEN1 RET
29 parathyroid carcinoma 10.1 CALCA MEN1 RET
30 gastroduodenal crohn's disease 10.1 GDNF GFRA1
31 cowper gland carcinoma 10.1 MEN1 RET
32 subserous uterine fibroid 10.1 CALCA MEN1 RET
33 connective tissue cancer 10.1 CALCA GDNF RET
34 endocrine gland cancer 10.1 CALCA MEN1 RET
35 shprintzen-goldberg syndrome 10.1 EDNRB GDNF RET
36 ariboflavinosis 10.1 EDNRB GDNF RET
37 mucositis 10.1
38 neuroma 10.1
39 spinal meningioma 10.1 EDNRB GDNF RET
40 isolated methylmalonic acidemia 10.1 GDNF RET
41 t-cell adult acute lymphocytic leukemia 10.1 PTCH1 RET
42 chronic infections, due to mbl deficiency 10.1 EDNRB GDNF RET
43 sweat gland cancer 10.1 EDNRB GDNF RET
44 corneal ulcer 10.1 CALCA GDNF
45 vestibulocochlear nerve disease 10.1 GDNF RET
46 t-cell large granular lymphocyte leukemia 10.1 MEN1 PTCH1 RET
47 multiple mucosal neuroma 10.0
48 aneurysm 10.0 CALCA GDNF MEN1 RET
49 urinary tract papillary transitional cell benign neoplasm 10.0 CALCA RET
50 benign shuddering attacks 10.0 CALCA MEN1 PTCH1 RET

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia Iib:



Diseases related to Multiple Endocrine Neoplasia Iib

Symptoms & Phenotypes for Multiple Endocrine Neoplasia Iib

Symptoms by clinical synopsis from OMIM:

162300

Clinical features from OMIM:

162300

Human phenotypes related to Multiple Endocrine Neoplasia Iib:

32 (show all 27)
id Description HPO Frequency HPO Source Accession
1 constipation 32 HP:0002019
2 diarrhea 32 HP:0002014
3 joint laxity 32 HP:0001388
4 pectus excavatum 32 HP:0000767
5 muscular hypotonia 32 HP:0001252
6 scoliosis 32 HP:0002650
7 kyphosis 32 HP:0002808
8 hyperlordosis 32 HP:0003307
9 global developmental delay 32 HP:0001263
10 thick eyebrow 32 HP:0000574
11 myopathy 32 HP:0003198
12 thick lower lip vermilion 32 HP:0000179
13 high, narrow palate 32 HP:0002705
14 pes cavus 32 HP:0001761
15 aganglionic megacolon 32 HP:0002251
16 pheochromocytoma 32 HP:0002666
17 disproportionate tall stature 32 HP:0001519
18 parathyroid hyperplasia 32 HP:0008208
19 failure to thrive in infancy 32 HP:0001531
20 abnormality of the skin 32 HP:0000951
21 medullary thyroid carcinoma 32 HP:0002865
22 ganglioneuroma 32 HP:0003005
23 nodular goiter 32 HP:0005994
24 elevated calcitonin 32 HP:0003528
25 colonic diverticula 32 HP:0002253
26 elevated urinary epinephrine 32 HP:0003639
27 proximal femoral epiphysiolysis 32 HP:0006461

UMLS symptoms related to Multiple Endocrine Neoplasia Iib:


constipation, diarrhea, joint laxity

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia Iib:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 GDNF GFRA1 NCK1 OSMR PTCH1 RET
2 cellular MP:0005384 10.02 GDNF GFRA1 MEN1 NCK1 PTCH1 RET
3 digestive/alimentary MP:0005381 10 EDNRB GDNF GFRA1 MEN1 PTCH1 RET
4 growth/size/body region MP:0005378 9.97 EDNRB GDNF MEN1 NCK1 OSMR PTCH1
5 embryo MP:0005380 9.91 EDNRB GFRA1 MEN1 NCK1 PTCH1 RET
6 endocrine/exocrine gland MP:0005379 9.88 EDNRB GDNF MEN1 OSMR PTCH1 RET
7 immune system MP:0005387 9.87 GDNF GFRA1 MEN1 OSMR PTCH1 RET
8 mortality/aging MP:0010768 9.86 EDNRB GDNF GFRA1 MEN1 NCK1 PTCH1
9 muscle MP:0005369 9.63 EDNRB GDNF GFRA1 MEN1 PTCH1 RET
10 nervous system MP:0003631 9.5 GFRA1 MEN1 NCK1 PTCH1 RET EDNRB
11 renal/urinary system MP:0005367 9.1 EDNRB GDNF GFRA1 NCK1 PTCH1 RET

Drugs & Therapeutics for Multiple Endocrine Neoplasia Iib

Drugs for Multiple Endocrine Neoplasia Iib (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
10 Albumin-Bound Paclitaxel Phase 3
11 Angiogenesis Inhibitors Phase 3
12 Angiogenesis Modulating Agents Phase 3
13 Antimitotic Agents Phase 3
14 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
15 Antidotes Phase 3,Phase 2
16 Anti-Infective Agents Phase 3,Phase 1,Phase 2
17 Antimetabolites Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
19 Antiviral Agents Phase 3,Phase 1,Phase 2
20 Hematinics Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Micronutrients Phase 3,Phase 2,Phase 1
23 Protective Agents Phase 3,Phase 2
24 Trace Elements Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 3,Phase 2,Phase 1
26 Vitamins Phase 3,Phase 2,Phase 1
27 Folate Nutraceutical Phase 3,Phase 2,Phase 1
28 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
29
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
30
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
31
Methyltestosterone Approved Phase 2 58-18-4 6010
32
Testosterone Approved, Investigational Phase 2 58-22-0 6013
33
Olaparib Approved Phase 2 763113-22-0 23725625
34
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
35
Zoledronic acid Approved Phase 2 118072-93-8 68740
36
Nelfinavir Approved Phase 2 159989-64-7 64143
37
Camptothecin Experimental Phase 2 7689-03-4
38
Enclomiphene Investigational Phase 2 15690-57-0
39
Cediranib Investigational Phase 2 288383-20-0 9933475
40 HIV Protease Inhibitors Phase 1, Phase 2
41
protease inhibitors Phase 1, Phase 2
42 Proteasome Inhibitors Phase 1, Phase 2
43 Belotecan Phase 2
44 topoisomerase I inhibitors Phase 2
45 Topoisomerase Inhibitors Phase 2,Phase 1
46 Anabolic Agents Phase 2
47 Androgens Phase 2
48 Antineoplastic Agents, Hormonal Phase 2
49 Clomiphene Phase 2
50 Estrogen Antagonists Phase 2

Interventional clinical trials:

(show all 20)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
2 Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection Recruiting NCT02506842 Phase 3
3 A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Completed NCT00923247 Phase 1, Phase 2
4 Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial Completed NCT01630018 Phase 2
5 Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism Completed NCT01270841 Phase 2
6 To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone Completed NCT00706719 Phase 2
7 DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Recruiting NCT02166905 Phase 1, Phase 2
8 Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer Recruiting NCT02889900 Phase 2
9 Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer Recruiting NCT03073785 Phase 2
10 Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer Recruiting NCT01959672 Phase 2
11 Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Active, not recruiting NCT00514046 Phase 1, Phase 2
12 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors Completed NCT02262455 Phase 1
13 Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib and Vorinostat in Resectable, Borderline Resectable or Unresectable Non-metastatic Pancreas Cancer Recruiting NCT02349867 Phase 1
14 Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT01606241 Phase 1
15 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Not yet recruiting NCT02831179 Phase 1
16 Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients Completed NCT01424878
17 Natural History Study of Children and Young Adults With Medullary Thyroid Cancer Recruiting NCT01660984
18 Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy Recruiting NCT02414100
19 Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery Active, not recruiting NCT02511821
20 An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC) Enrolling by invitation NCT01511393

Search NIH Clinical Center for Multiple Endocrine Neoplasia Iib

Cochrane evidence based reviews: multiple endocrine neoplasia type 2b

Genetic Tests for Multiple Endocrine Neoplasia Iib

Genetic tests related to Multiple Endocrine Neoplasia Iib:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia, Type 2b 29
2 Multiple Endocrine Neoplasia Type 2b 24

Anatomical Context for Multiple Endocrine Neoplasia Iib

MalaCards organs/tissues related to Multiple Endocrine Neoplasia Iib:

39
Thyroid, Skin, Colon, Prostate

Publications for Multiple Endocrine Neoplasia Iib

Articles related to Multiple Endocrine Neoplasia Iib:

id Title Authors Year
1
Cutaneous metastasis of pheochromocytoma in multiple endocrine neoplasia IIB. ( 16844526 )
2006
2
The significance of cystic adrenal lesions in multiple endocrine neoplasia IIB syndrome. ( 15455172 )
2004
3
Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. ( 7853568 )
1995
4
Multiple endocrine neoplasia IIb: an unusual cause of chronic constipation. ( 1967640 )
1990
5
Early total thyroidectomy in patients with multiple endocrine neoplasia IIb syndrome. ( 2573160 )
1989

Variations for Multiple Endocrine Neoplasia Iib

UniProtKB/Swiss-Prot genetic disease variations for Multiple Endocrine Neoplasia Iib:

66
id Symbol AA change Variation ID SNP ID
1 RET p.Met918Thr VAR_006342 rs74799832
2 RET p.Thr946Met VAR_006345
3 RET p.Ala883Phe VAR_009485 rs377767429

ClinVar genetic disease variations for Multiple Endocrine Neoplasia Iib:

6 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1 RET NM_020975.4(RET): c.1901G> A (p.Cys634Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs75996173 GRCh37 Chromosome 10, 43609949: 43609949
2 RET NM_020630.4(RET): c.1859G> A (p.Cys620Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs77503355 GRCh37 Chromosome 10, 43609103: 43609103
3 RET NM_020975.4(RET): c.1900T> C (p.Cys634Arg) single nucleotide variant Pathogenic/Likely pathogenic rs75076352 GRCh37 Chromosome 10, 43609948: 43609948
4 RET NM_020630.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic/Likely pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
5 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic/Likely pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
6 RET NM_020630.4(RET): c.1859G> T (p.Cys620Phe) single nucleotide variant Pathogenic rs77503355 GRCh37 Chromosome 10, 43609103: 43609103
7 RET NM_020630.4(RET): c.1852T> C (p.Cys618Arg) single nucleotide variant Pathogenic/Likely pathogenic rs76262710 GRCh37 Chromosome 10, 43609096: 43609096
8 RET NM_020630.4(RET): c.2304G> C (p.Glu768Asp) single nucleotide variant Pathogenic/Likely pathogenic rs78014899 GRCh37 Chromosome 10, 43613840: 43613840
9 RET NM_020975.4(RET): c.1826G> A (p.Cys609Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs77939446 GRCh37 Chromosome 10, 43609070: 43609070
10 RET NM_020975.4(RET): c.2410G> A (p.Val804Met) single nucleotide variant Pathogenic rs79658334 GRCh37 Chromosome 10, 43614996: 43614996
11 RET NM_020975.4(RET): c.2671T> G (p.Ser891Ala) single nucleotide variant Pathogenic/Likely pathogenic rs75234356 GRCh37 Chromosome 10, 43615592: 43615592
12 RET NM_020975.4(RET): c.1853G> A (p.Cys618Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs79781594 GRCh37 Chromosome 10, 43609097: 43609097
13 RET NM_020630.4(RET): c.1888T> C (p.Cys630Arg) single nucleotide variant Pathogenic/Likely pathogenic rs377767404 GRCh37 Chromosome 10, 43609936: 43609936
14 RET NM_020630.4(RET): c.2304G> T (p.Glu768Asp) single nucleotide variant Pathogenic/Likely pathogenic rs78014899 GRCh37 Chromosome 10, 43613840: 43613840
15 RET NM_020630.4(RET): c.2410G> C (p.Val804Leu) single nucleotide variant Pathogenic/Likely pathogenic rs79658334 GRCh37 Chromosome 10, 43614996: 43614996
16 RET NM_020975.4(RET): c.2647_2648delGCinsTT (p.Ala883Phe) indel Pathogenic/Likely pathogenic rs377767429 GRCh37 Chromosome 10, 43615568: 43615569

Expression for Multiple Endocrine Neoplasia Iib

Search GEO for disease gene expression data for Multiple Endocrine Neoplasia Iib.

Pathways for Multiple Endocrine Neoplasia Iib

Pathways related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 CALCA EDNRB GDNF GFRA1 MEN1 NCK1
2 11.74 NCK1 PTCH1 RYK
3
Show member pathways
11.48 GDNF GFRA1 NCK1 RET
4 10.97 GDNF GFRA1
5 10.9 CALCA EDNRB
6 10.9 GDNF GFRA1 RET
7 10.5 GDNF GFRA1 NCK1 RET

GO Terms for Multiple Endocrine Neoplasia Iib

Biological processes related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.76 EDNRB GDNF GFRA1 RET
2 MAPK cascade GO:0000165 9.67 GDNF GFRA1 MEN1 RET
3 axon guidance GO:0007411 9.62 GDNF GFRA1 RET RYK
4 ureteric bud development GO:0001657 9.51 GDNF RET
5 branching involved in ureteric bud morphogenesis GO:0001658 9.49 GDNF PTCH1
6 negative regulation of osteoblast differentiation GO:0045668 9.48 MEN1 PTCH1
7 peripheral nervous system development GO:0007422 9.43 EDNRB GDNF
8 vasodilation GO:0042311 9.4 CALCA EDNRB
9 neural crest cell migration GO:0001755 9.33 EDNRB GDNF RET
10 posterior midgut development GO:0007497 9.26 EDNRB RET
11 response to pain GO:0048265 9.13 CALCA EDNRB RET
12 enteric nervous system development GO:0048484 8.8 EDNRB GDNF RET

Molecular functions related to Multiple Endocrine Neoplasia Iib according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.26 CALCA GDNF GFRA1 NCK1
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.8 GDNF GFRA1 RET

Sources for Multiple Endocrine Neoplasia Iib

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....